Cargando…

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Detalles Bibliográficos
Autores principales:	Llibre, JM, Martínez, E, Barreiro, P, Escrig, R, Ribera, E, Cervantes, M, Imaz, A, Gutierrez, F, Knobel, H, Ornelas, A, Zamora, FX, Clotet, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113037/ http://dx.doi.org/10.1186/1758-2652-13-S4-P35

Ejemplares similares

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
por: Landonio, S, et al.
Publicado: (2010)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
por: Bhagwat, Priya, et al.
Publicado: (2018)

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy
por: Deshwal, Rajesh, et al.
Publicado: (2019)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir
por: Patiño Escarcina, Jesús Enrique, et al.
Publicado: (2023)

Dual therapy based on raltegravir and boosted protease inhibitors – the experience of Polish centers
por: Jabłonowska, Elżbieta, et al.
Publicado: (2016)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
por: Negredo, Eugènia, et al.
Publicado: (2020)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
por: Noguera-Julian, Marc, et al.
Publicado: (2013)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Reduction of the HIV Protease Inhibitor-Induced ER Stress and Inflammatory Response by Raltegravir in Macrophages
por: Zhang, Xiaoxuan, et al.
Publicado: (2014)

Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study
por: Echeverría, Patricia, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
por: Larru, Beatriz, et al.
Publicado: (2007)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

936 Tolerability, Adherence and Completion of New Occupational HIV Post-Exposure Prophylaxis Regimens (Tenofovir + Emtricitabine and Raltegravir)
por: Bock, Izona, et al.
Publicado: (2014)

Micronucleated Erythrocytes in Newborn Rats Exposed to Raltegravir Placental Transfer
por: Torres-Mendoza, Blanca Miriam, et al.
Publicado: (2014)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
por: Puertas, Maria C, et al.
Publicado: (2018)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

Switching Virally Suppressed, Treatment-Experienced Patients to a Raltegravir-Containing Regimen Does Not Alter Levels of HIV-1 DNA
por: Lam, Yu Ming Paul, et al.
Publicado: (2012)

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen
por: Cavaco-Silva, Joana, et al.
Publicado: (2014)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Raltegravir: molecular basis of its mechanism of action
por: Mouscadet, Jean-François, et al.
Publicado: (2009)

886. Pregnancy Outcomes Following Raltegravir Exposure
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Low raltegravir transfer into the breastmilk of a woman living with HIV
por: Feiterna-Sperling, Cornelia, et al.
Publicado: (2020)

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
por: Capetti, Amedeo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sl6aqqs2cnb3e5lbu9i4ae4ng4